A huge water outage has struck nearly 60,000 homes and left supplies running dry for schools in Hampshire. Homes in ...

Ustekinumab-stba, manufactured by Celltrion, is expected to be marketed in the United States in February 2025.

Ms Woolger lives with ulcerative colitis, which is an inflammatory bowel disease that can cause ulcers, and psoriatic arthritis, and said her autoimmune conditions can make her “more prone to ...

Gabe, Volpe's son was diagnosed with pan- ulcerative colitis and his treatment path was filled with complications leaving him exhausted, underweight, and socially isolated.

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...

Gabe, Volpe's son was diagnosed with pan- ulcerative colitis and his treatment path was filled with complications leaving him ...

We recently published a list of the Jim Cramer Just Discussed These 13 Stocks. In this article, we are going to take a look ...

Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting ...

Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Barclays analyst Balaji Prasad raised the firm’s price target on Teva (TEVA) to $28 from $25 and keeps an Overweight rating on the shares. The ...

Teva and Sanofi report breakthrough results for duvakitug, showing strong efficacy in IBD. Learn how this TL1A drug could ...